ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies

ENaC inhibition with BI 1265162 is a promising strategy to optimise outcomes in patients with CF either eligible, or ineligible, for CFTR modulator therapy. Phase II clinical trials of BI 1265162 must now show this translates into clinical benefit. https://bit.ly/2OQ1IUI

Detalles Bibliográficos
Autor principal: Mall, Marcus A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Research Highlights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758539/
https://www.ncbi.nlm.nih.gov/pubmed/32732328
http://dx.doi.org/10.1183/13993003.00946-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758539/
https://www.ncbi.nlm.nih.gov/pubmed/32732328
http://dx.doi.org/10.1183/13993003.00946-2020

Ejemplares similares